Literature DB >> 18650472

Lack of RPS14 promoter aberrant methylation supports the haploinsufficiency model for the 5q- syndrome.

Ana Valencia, Jose Cervera, Esperanza Such, Miguel A Sanz, Guillermo F Sanz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18650472     DOI： 10.1182/blood-2008-05-159707

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

Review 1.  Molecular dissection of the 5q deletion in myelodysplastic syndrome.

Authors:  Benjamin L Ebert
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

2.  Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival.

Authors:  Akos Czibere; Ingmar Bruns; Bärbel Junge; Raminder Singh; Guido Kobbe; Rainer Haas; Ulrich Germing
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

3.  Assessing karyotype precision by microarray-based comparative genomic hybridization in the myelodysplastic/myeloproliferative syndromes.

Authors:  Marilyn L Slovak; David D Smith; Victoria Bedell; Ya-Hsuan Hsu; Margaret O'Donnell; Stephen J Forman; Karl Gaal; Lisa McDaniel; Roger Schultz; Blake C Ballif; Lisa G Shaffer
Journal:  Mol Cytogenet       Date:  2010-11-15       Impact factor: 2.009

4.  Important genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway.

Authors:  Ota Fuchs
Journal:  Leuk Res Treatment       Date:  2012-02-13

Review 5.  Targeting low-risk myelodysplastic syndrome with novel therapeutic strategies.

Authors:  Gaurang Trivedi; Daichi Inoue; Lingbo Zhang
Journal:  Trends Mol Med       Date:  2021-07-11       Impact factor: 15.272
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.